Dynamic solutionLtd（A290660）株式概要株式会社ネオフェクトは、脳卒中や脊髄損傷などのリハビリテーション医療機器・コンテンツの研究・開発・製造・販売を行っています。 詳細A290660 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 過去5年間で収益は年間7.7%減少しました。 KR市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( ₩79B )すべてのリスクチェックを見るA290660 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩939.001.1k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-18b26b2016201920222025202620282031Revenue ₩11.9bEarnings ₩1.5bAdvancedSet Fair ValueView all narrativesDynamic solution Co.,Ltd. 競合他社RaySymbol: KOSDAQ:A228670Market cap: ₩71.6bSugentechSymbol: KOSDAQ:A253840Market cap: ₩73.8bRayenceSymbol: KOSDAQ:A228850Market cap: ₩107.0bHuvitzSymbol: KOSDAQ:A065510Market cap: ₩75.5b価格と性能株価の高値、安値、推移の概要Dynamic solutionLtd過去の株価現在の株価₩939.0052週高値₩9,590.0052週安値₩770.00ベータ-0.331ヶ月の変化-4.57%3ヶ月変化-82.43%1年変化-79.02%3年間の変化-87.74%5年間の変化-95.02%IPOからの変化-97.56%最新ニュースNew Risk • Jun 01New major risk - Revenue and earnings growthEarnings have declined by 7.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 7.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩71.7b market cap, or US$47.5m).お知らせ • May 14Dynamic solution Co.,Ltd. announced that it expects to receive KRW 5 billion in fundingDynamic solution Co.,Ltd. announced private placement to issue 2% Series 10 Unregistered Interest Unsecured Private Convertible Bonds due May 21, 2029 for gross proceeds of KRW 5,000,000,000 on May 13, 2026. The transaction includes participation from Mirae Asset Securities Co., Ltd.(From the status of the fund's trustee). The bonds bear 2% interest rate, 4% yield to maturity and will have a maturity date of May 21, 2029. The bonds are 100% convertible into 4,382,120 common shares at a conversion price of KRW 1,141 at a conversion period from May 21, 2027 to April 21, 2029. The bonds are restricted for 1 year. The transaction is approved by board of directors of the company and is expected to close on May 21, 2026.お知らせ • Mar 25Neofect Co., Ltd. announced that it expects to receive KRW 20 billion in fundingNeofect Co., Ltd announced a private placement to issue Series 9 Unsecured Private Convertible Bonds for the proceeds of KRW 20,000,000,000 on March 24, 2026. Bond bear 1% interest and 3% yield to maturity. Transaction involves participation of Bronte New Technology Fund No. 83 as an investor. Bond matures on May 27, 2029 and conversion price is KRW 1,347. Transaction is approved by board of directors and is expected to close May 27, 2026. Bonds have 1 year hold period.Reported Earnings • Mar 21Full year 2025 earnings released: ₩218 loss per share (vs ₩45.98 loss in FY 2024)Full year 2025 results: ₩218 loss per share (further deteriorated from ₩45.98 loss in FY 2024). Revenue: ₩16.1b (down 7.1% from FY 2024). Net loss: ₩10.8b (loss widened 468% from FY 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Mar 12Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South KoreaNew Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩65.4b market cap, or US$45.7m).最新情報をもっと見るRecent updatesNew Risk • Jun 01New major risk - Revenue and earnings growthEarnings have declined by 7.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 7.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩71.7b market cap, or US$47.5m).お知らせ • May 14Dynamic solution Co.,Ltd. announced that it expects to receive KRW 5 billion in fundingDynamic solution Co.,Ltd. announced private placement to issue 2% Series 10 Unregistered Interest Unsecured Private Convertible Bonds due May 21, 2029 for gross proceeds of KRW 5,000,000,000 on May 13, 2026. The transaction includes participation from Mirae Asset Securities Co., Ltd.(From the status of the fund's trustee). The bonds bear 2% interest rate, 4% yield to maturity and will have a maturity date of May 21, 2029. The bonds are 100% convertible into 4,382,120 common shares at a conversion price of KRW 1,141 at a conversion period from May 21, 2027 to April 21, 2029. The bonds are restricted for 1 year. The transaction is approved by board of directors of the company and is expected to close on May 21, 2026.お知らせ • Mar 25Neofect Co., Ltd. announced that it expects to receive KRW 20 billion in fundingNeofect Co., Ltd announced a private placement to issue Series 9 Unsecured Private Convertible Bonds for the proceeds of KRW 20,000,000,000 on March 24, 2026. Bond bear 1% interest and 3% yield to maturity. Transaction involves participation of Bronte New Technology Fund No. 83 as an investor. Bond matures on May 27, 2029 and conversion price is KRW 1,347. Transaction is approved by board of directors and is expected to close May 27, 2026. Bonds have 1 year hold period.Reported Earnings • Mar 21Full year 2025 earnings released: ₩218 loss per share (vs ₩45.98 loss in FY 2024)Full year 2025 results: ₩218 loss per share (further deteriorated from ₩45.98 loss in FY 2024). Revenue: ₩16.1b (down 7.1% from FY 2024). Net loss: ₩10.8b (loss widened 468% from FY 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Mar 12Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South KoreaNew Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩65.4b market cap, or US$45.7m).分析記事 • Jan 11Some Shareholders Feeling Restless Over Neofect Co., Ltd.'s (KOSDAQ:290660) P/S RatioWith a median price-to-sales (or "P/S") ratio of close to 2.4x in the Medical Equipment industry in Korea, you could be...New Risk • Jan 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩51.6b market cap, or US$35.7m).New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩44.4b market cap, or US$30.8m).お知らせ • Nov 28Neofect Co., Ltd. announced that it has received KRW 5.49999938 billion in funding from Yeomi Midia Co. Ltd.,On November 27, 2025. Neofect Co., Ltd. announced that it has closed the transaction.お知らせ • Oct 14Neofect Co., Ltd. announced that it has received KRW 1 billion in funding from Organ Eco Tech Co.,Ltd.On October 13, 2025, Neofect Co., Ltd. closed the transaction.分析記事 • Sep 28Some Confidence Is Lacking In Neofect Co., Ltd. (KOSDAQ:290660) As Shares Slide 26%To the annoyance of some shareholders, Neofect Co., Ltd. ( KOSDAQ:290660 ) shares are down a considerable 26% in the...お知らせ • Aug 21Mildred Co., Ltd. completed the acquisition of Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660).Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion on July 29, 2025. As part of acquisition, 23,000,000 shares will be acquired. As part of consideration KRW 1.23 billion will be paid on contract signing date and balance of KRW 11.07 billion will be paid at closing date. For the period ending December 31, 2024, Knightsbridge Co., Ltd. reported sales of KRW 1.96 billion and net income of KRW 405.85 million. As of December 31, 2024, Knightsbridge Co., Ltd. reported total debt of KRW 199.39 million, total assets of KRW 13.84 billion and total common equity of KRW 13.64 billion. The expected completion of the transaction is August 31, 2025. As of August 19, 2025, the deal is expected to complete on August 19, 2025. Mildred Co., Ltd. completed the acquisition of Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) on August 19, 2025.Reported Earnings • Aug 14Second quarter 2025 earnings released: ₩327 loss per share (vs ₩82.00 profit in 2Q 2024)Second quarter 2025 results: ₩327 loss per share (down from ₩82.00 profit in 2Q 2024). Revenue: ₩6.20b (up 15% from 2Q 2024). Net loss: ₩15.1b (down ₩18.5b from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Aug 13Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund completed the acquisition of 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others.Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund agreed to acquire 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others for KRW 27 billion on June 27, 2025. A cash consideration of KRW 27 billion valued at KRW 2000 per share will be paid by Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund for 13.5 million shares of Neofect Co., Ltd. As part of consideration, KRW 27 billion is paid towards common equity of Neofect Co., Ltd. Post the transaction, Scandi New Technology Association No. 278 will hold 3.16% stake in Neofect Co., Ltd. The expected completion of the transaction is August 13, 2025. Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund completed the acquisition of 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others on August 12, 2025.分析記事 • Jul 30Revenues Not Telling The Story For Neofect Co., Ltd. (KOSDAQ:290660)When you see that almost half of the companies in the Medical Equipment industry in Korea have price-to-sales ratios...お知らせ • Jul 29Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion.Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion on July 29, 2025. As part of acquisition, 23,000,000 shares will be acquired. As part of consideration KRW 1.23 billion will be paid on contract signing date and balance of KRW 11.07 billion will be paid at closing date. For the period ending December 31, 2024, Knightsbridge Co., Ltd. reported sales of KRW 1.96 billion and net income of KRW 405.85 million. As of December 31, 2024, Knightsbridge Co., Ltd. reported total debt of KRW 199.39 million, total assets of KRW 13.84 billion and total common equity of KRW 13.64 billion. The expected completion of the transaction is August 31, 2025.New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₩65.2b market cap, or US$47.2m).お知らせ • Jun 20Neofect Co., Ltd. announced that it expects to receive KRW 12 billion in fundingNeofect Co., Ltd announced a private placement to issue 7,500,000 shares at an issue price of KRW 800 per share for gross proceeds of KRW 6,000,000,000 on June 18, 2025. The transaction will include participation from new investor Fleur New Technology Fund No. 91. The transaction has been approved by shareholders, restricted to a hold period, expected to close on August 18, 2025. 7,500,000 shares - The company will issue 7,500,000 shares at an issue price of KRW 800 per share gross proceeds of KRW 6,000,000,000; aggregate gross proceeds of KRW 12,000,000,000. The transaction will include participation from new investor Sion New Technology Fund No. 90. The transaction has been approved by shareholders, restricted to a hold period, expected to close on July 18, 2025.New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩54.4b market cap, or US$39.6m).お知らせ • Mar 14Neofect Co., Ltd., Annual General Meeting, Mar 28, 2025Neofect Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (35% increase in shares outstanding). Market cap is less than US$100m (₩40.9b market cap, or US$28.5m).分析記事 • Dec 04Investor Optimism Abounds Neofect Co., Ltd. (KOSDAQ:290660) But Growth Is LackingWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...お知らせ • Oct 22Neofect Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999675 million.Neofect Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999675 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,145,475 Price\Range: KRW 873 Transaction Features: Subsequent Direct Listingお知らせ • Oct 17Neofect Co., Ltd. announced that it expects to receive KRW 1.99999935 billion in funding from Aprogen I&C, Inc.Neofect Co., Ltd. announced a private placement to issue 2,290,950 common shares at an issue price of KRW 873 per share for the gross proceeds of KRW 1,999,999,350 on October 15, 2024. The transaction will include participation from new investor Aprogen I&C, Inc. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on October 23, 2024.お知らせ • Oct 09Neofect Co., Ltd. announced that it expects to receive KRW 999.999675 million in funding from Cj Consulting Co., Ltd., YR Invest Co., LtdNeofect Co., Ltd. announced a private placemen to issue 1,145,475 shares at an issue price of KRW 873 per share for the gross proceeds of KRW 999,999,675 on October 8, 2024. The transaction will include participation from new investors Cj Consulting Co., Ltd. 916,380 shares and YR Invest Co., Ltd 229,095 shares. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on October 21, 2024.分析記事 • Jun 19There Is A Reason Neofect Co.,Ltd's (KOSDAQ:290660) Price Is UndemandingWith a price-to-sales (or "P/S") ratio of 1.6x Neofect Co.,Ltd ( KOSDAQ:290660 ) may be sending bullish signals at the...お知らせ • Apr 10Neofect Co.,Ltd announced that it has received KRW 4.99999991 billion in funding from Scandi New Technology Association No. 278On April 9, 2024, Neofect Co.,Ltd. closed the transaction. The company issued 2,722,323 common shares at an issue price of KRW 1,102 for the gross proceeds of KRW 2,999,999,946 in its second and final tranche closing. The company has received KRW 4,999,999,910 in the transaction.お知らせ • Dec 28Neofect Co.,Ltd announced that it has received KRW 4.99999991 billion in funding from Kyowon Life, Inc., Scandi New Technology Association No. 278On December 26, 2023, Neofect Co.,Ltd. closed the transaction. The company received KRW 1,999,999,964 in its second and final tranche closing.New Risk • Nov 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.0b market cap, or US$28.7m).New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩6.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩35.6b market cap, or US$27.3m).お知らせ • Jan 17Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 999.999245 million.Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 999.999245 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 692,041 Price\Range: KRW 1445 Transaction Features: Subsequent Direct Listing分析記事 • Mar 17NeofectLtd's (KOSDAQ:290660) Stock Price Has Reduced 19% In The Past YearIt's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...Is New 90 Day High Low • Feb 24New 90-day low: ₩3,015The company is down 16% from its price of ₩3,570 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period.Is New 90 Day High Low • Feb 03New 90-day low: ₩3,105The company is down 19% from its price of ₩3,810 on 05 November 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.Is New 90 Day High Low • Jan 18New 90-day low: ₩3,215The company is down 16% from its price of ₩3,815 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 7.0% over the same period.Is New 90 Day High Low • Dec 28New 90-day low: ₩3,405The company is down 25% from its price of ₩4,545 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 4.0% over the same period.Is New 90 Day High Low • Dec 08New 90-day low: ₩3,510The company is down 10.0% from its price of ₩3,905 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 2.0% over the same period.Reported Earnings • Dec 06Third quarter 2020 earnings released: ₩309 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: ₩4.35b (down 15% from 3Q 2019). Net loss: ₩3.80b (loss widened 7.6% from 3Q 2019).お知らせ • Nov 12Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 18.59 billion.Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 18.59 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,500,000 Price\Range: KRW 2860 Discount Per Security: KRW 64.35 Transaction Features: ESOP Related Offering; Rights OfferingIs New 90 Day High Low • Oct 26New 90-day low: ₩3,540The company is down 29% from its price of ₩5,020 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period.株主還元A290660KR Medical EquipmentKR 市場7D0%-4.5%-0.3%1Y-79.0%-18.1%165.0%株主還元を見る業界別リターン: A290660過去 1 年間で-18.1 % の収益を上げたKR Medical Equipment業界を下回りました。リターン対市場: A290660は、過去 1 年間で165 % のリターンを上げたKR市場を下回りました。価格変動Is A290660's price volatile compared to industry and market?A290660 volatilityA290660 Average Weekly Movement29.4%Medical Equipment Industry Average Movement8.4%Market Average Movement8.7%10% most volatile stocks in KR Market16.2%10% least volatile stocks in KR Market4.5%安定した株価: A290660の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A290660の 週次ボラティリティ は、過去 1 年間で19%から29%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト201057Ho-young Banwww.neofect.com株式会社ネオフェクトは、脳卒中や脊髄損傷などのリハビリテーション医療機器・コンテンツの研究・開発・製造・販売を行っている。加速度センサーと屈曲センサーで前腕、手首、指の動きを測定するハイテクリハビリ機器「ネオフェクト・スマート・グローブ」、小児の手のリハビリ用「ネオフェクト・スマート・キッズ」、ユーザーの肩と上腕の動きを開発し、機能的なリーチと筋肉コントロールの向上を促進するハイテク医療機器「ネオフェクト・スマート・ボード」、実際のトレーニングシナリオでバランスと姿勢を練習する「ネオフェクト・スマート・バランス」、機能的・認知的リハビリ用デジタルペグボード「ネオフェクト・スマート・ペグボード」などを提供している。また、認知症予防・リハビリテーションプログラム「ネオフェクト・スマート・テーブル」、装着型ロボット手袋「ネオマノ」、脳卒中、認知症、外傷性脳損傷、脳腫瘍、脳性麻痺の患者を支援する認知リハビリテーションプログラム「ネオフェクト・コムコグ」、遠隔リハビリテーション用に設計された遠隔治療プラットフォーム「ネオフェクト・テレリハ」、各種装具・補助器具も提供している。同社は2010年に法人化され、韓国の城南市に本社を置いている。もっと見るDynamic solution Co.,Ltd. 基礎のまとめDynamic solutionLtd の収益と売上を時価総額と比較するとどうか。A290660 基礎統計学時価総額₩78.99b収益（TTM）-₩14.37b売上高(TTM)₩15.46b5.1xP/Sレシオ-5.5xPER（株価収益率A290660 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A290660 損益計算書（TTM）収益₩15.46b売上原価₩8.55b売上総利益₩6.91bその他の費用₩21.28b収益-₩14.37b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-170.80グロス・マージン44.69%純利益率-92.95%有利子負債／自己資本比率17.5%A290660 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/15 02:17終値2026/06/04 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dynamic solution Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 01New major risk - Revenue and earnings growthEarnings have declined by 7.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 7.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩71.7b market cap, or US$47.5m).
お知らせ • May 14Dynamic solution Co.,Ltd. announced that it expects to receive KRW 5 billion in fundingDynamic solution Co.,Ltd. announced private placement to issue 2% Series 10 Unregistered Interest Unsecured Private Convertible Bonds due May 21, 2029 for gross proceeds of KRW 5,000,000,000 on May 13, 2026. The transaction includes participation from Mirae Asset Securities Co., Ltd.(From the status of the fund's trustee). The bonds bear 2% interest rate, 4% yield to maturity and will have a maturity date of May 21, 2029. The bonds are 100% convertible into 4,382,120 common shares at a conversion price of KRW 1,141 at a conversion period from May 21, 2027 to April 21, 2029. The bonds are restricted for 1 year. The transaction is approved by board of directors of the company and is expected to close on May 21, 2026.
お知らせ • Mar 25Neofect Co., Ltd. announced that it expects to receive KRW 20 billion in fundingNeofect Co., Ltd announced a private placement to issue Series 9 Unsecured Private Convertible Bonds for the proceeds of KRW 20,000,000,000 on March 24, 2026. Bond bear 1% interest and 3% yield to maturity. Transaction involves participation of Bronte New Technology Fund No. 83 as an investor. Bond matures on May 27, 2029 and conversion price is KRW 1,347. Transaction is approved by board of directors and is expected to close May 27, 2026. Bonds have 1 year hold period.
Reported Earnings • Mar 21Full year 2025 earnings released: ₩218 loss per share (vs ₩45.98 loss in FY 2024)Full year 2025 results: ₩218 loss per share (further deteriorated from ₩45.98 loss in FY 2024). Revenue: ₩16.1b (down 7.1% from FY 2024). Net loss: ₩10.8b (loss widened 468% from FY 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Mar 12Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
New Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩65.4b market cap, or US$45.7m).
New Risk • Jun 01New major risk - Revenue and earnings growthEarnings have declined by 7.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 7.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩71.7b market cap, or US$47.5m).
お知らせ • May 14Dynamic solution Co.,Ltd. announced that it expects to receive KRW 5 billion in fundingDynamic solution Co.,Ltd. announced private placement to issue 2% Series 10 Unregistered Interest Unsecured Private Convertible Bonds due May 21, 2029 for gross proceeds of KRW 5,000,000,000 on May 13, 2026. The transaction includes participation from Mirae Asset Securities Co., Ltd.(From the status of the fund's trustee). The bonds bear 2% interest rate, 4% yield to maturity and will have a maturity date of May 21, 2029. The bonds are 100% convertible into 4,382,120 common shares at a conversion price of KRW 1,141 at a conversion period from May 21, 2027 to April 21, 2029. The bonds are restricted for 1 year. The transaction is approved by board of directors of the company and is expected to close on May 21, 2026.
お知らせ • Mar 25Neofect Co., Ltd. announced that it expects to receive KRW 20 billion in fundingNeofect Co., Ltd announced a private placement to issue Series 9 Unsecured Private Convertible Bonds for the proceeds of KRW 20,000,000,000 on March 24, 2026. Bond bear 1% interest and 3% yield to maturity. Transaction involves participation of Bronte New Technology Fund No. 83 as an investor. Bond matures on May 27, 2029 and conversion price is KRW 1,347. Transaction is approved by board of directors and is expected to close May 27, 2026. Bonds have 1 year hold period.
Reported Earnings • Mar 21Full year 2025 earnings released: ₩218 loss per share (vs ₩45.98 loss in FY 2024)Full year 2025 results: ₩218 loss per share (further deteriorated from ₩45.98 loss in FY 2024). Revenue: ₩16.1b (down 7.1% from FY 2024). Net loss: ₩10.8b (loss widened 468% from FY 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Mar 12Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026Neofect Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
New Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩65.4b market cap, or US$45.7m).
分析記事 • Jan 11Some Shareholders Feeling Restless Over Neofect Co., Ltd.'s (KOSDAQ:290660) P/S RatioWith a median price-to-sales (or "P/S") ratio of close to 2.4x in the Medical Equipment industry in Korea, you could be...
New Risk • Jan 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩51.6b market cap, or US$35.7m).
New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩44.4b market cap, or US$30.8m).
お知らせ • Nov 28Neofect Co., Ltd. announced that it has received KRW 5.49999938 billion in funding from Yeomi Midia Co. Ltd.,On November 27, 2025. Neofect Co., Ltd. announced that it has closed the transaction.
お知らせ • Oct 14Neofect Co., Ltd. announced that it has received KRW 1 billion in funding from Organ Eco Tech Co.,Ltd.On October 13, 2025, Neofect Co., Ltd. closed the transaction.
分析記事 • Sep 28Some Confidence Is Lacking In Neofect Co., Ltd. (KOSDAQ:290660) As Shares Slide 26%To the annoyance of some shareholders, Neofect Co., Ltd. ( KOSDAQ:290660 ) shares are down a considerable 26% in the...
お知らせ • Aug 21Mildred Co., Ltd. completed the acquisition of Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660).Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion on July 29, 2025. As part of acquisition, 23,000,000 shares will be acquired. As part of consideration KRW 1.23 billion will be paid on contract signing date and balance of KRW 11.07 billion will be paid at closing date. For the period ending December 31, 2024, Knightsbridge Co., Ltd. reported sales of KRW 1.96 billion and net income of KRW 405.85 million. As of December 31, 2024, Knightsbridge Co., Ltd. reported total debt of KRW 199.39 million, total assets of KRW 13.84 billion and total common equity of KRW 13.64 billion. The expected completion of the transaction is August 31, 2025. As of August 19, 2025, the deal is expected to complete on August 19, 2025. Mildred Co., Ltd. completed the acquisition of Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) on August 19, 2025.
Reported Earnings • Aug 14Second quarter 2025 earnings released: ₩327 loss per share (vs ₩82.00 profit in 2Q 2024)Second quarter 2025 results: ₩327 loss per share (down from ₩82.00 profit in 2Q 2024). Revenue: ₩6.20b (up 15% from 2Q 2024). Net loss: ₩15.1b (down ₩18.5b from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Aug 13Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund completed the acquisition of 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others.Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund agreed to acquire 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others for KRW 27 billion on June 27, 2025. A cash consideration of KRW 27 billion valued at KRW 2000 per share will be paid by Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund for 13.5 million shares of Neofect Co., Ltd. As part of consideration, KRW 27 billion is paid towards common equity of Neofect Co., Ltd. Post the transaction, Scandi New Technology Association No. 278 will hold 3.16% stake in Neofect Co., Ltd. The expected completion of the transaction is August 13, 2025. Petafield Co., Ltd., GY Healthcare No. 2 Investment Fund, GY Healthcare No. 3 Investment Fund and GY Healthcare No. 4 Investment Fund completed the acquisition of 27.9% stake in Neofect Co., Ltd. (KOSDAQ:A290660) from Scandi New Technology Association No. 278, Lxwidwin investment Fund 1 and Cheongdam Medicare New Technology Union 1 and others on August 12, 2025.
分析記事 • Jul 30Revenues Not Telling The Story For Neofect Co., Ltd. (KOSDAQ:290660)When you see that almost half of the companies in the Medical Equipment industry in Korea have price-to-sales ratios...
お知らせ • Jul 29Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion.Mildred Co., Ltd. agreed to acquire Knightsbridge Co., Ltd. from Neofect Co., Ltd. (KOSDAQ:A290660) for KRW 12.3 billion on July 29, 2025. As part of acquisition, 23,000,000 shares will be acquired. As part of consideration KRW 1.23 billion will be paid on contract signing date and balance of KRW 11.07 billion will be paid at closing date. For the period ending December 31, 2024, Knightsbridge Co., Ltd. reported sales of KRW 1.96 billion and net income of KRW 405.85 million. As of December 31, 2024, Knightsbridge Co., Ltd. reported total debt of KRW 199.39 million, total assets of KRW 13.84 billion and total common equity of KRW 13.64 billion. The expected completion of the transaction is August 31, 2025.
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₩65.2b market cap, or US$47.2m).
お知らせ • Jun 20Neofect Co., Ltd. announced that it expects to receive KRW 12 billion in fundingNeofect Co., Ltd announced a private placement to issue 7,500,000 shares at an issue price of KRW 800 per share for gross proceeds of KRW 6,000,000,000 on June 18, 2025. The transaction will include participation from new investor Fleur New Technology Fund No. 91. The transaction has been approved by shareholders, restricted to a hold period, expected to close on August 18, 2025. 7,500,000 shares - The company will issue 7,500,000 shares at an issue price of KRW 800 per share gross proceeds of KRW 6,000,000,000; aggregate gross proceeds of KRW 12,000,000,000. The transaction will include participation from new investor Sion New Technology Fund No. 90. The transaction has been approved by shareholders, restricted to a hold period, expected to close on July 18, 2025.
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩54.4b market cap, or US$39.6m).
お知らせ • Mar 14Neofect Co., Ltd., Annual General Meeting, Mar 28, 2025Neofect Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 42, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (35% increase in shares outstanding). Market cap is less than US$100m (₩40.9b market cap, or US$28.5m).
分析記事 • Dec 04Investor Optimism Abounds Neofect Co., Ltd. (KOSDAQ:290660) But Growth Is LackingWith a median price-to-sales (or "P/S") ratio of close to 2.2x in the Medical Equipment industry in Korea, you could be...
お知らせ • Oct 22Neofect Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999675 million.Neofect Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.999675 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,145,475 Price\Range: KRW 873 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 17Neofect Co., Ltd. announced that it expects to receive KRW 1.99999935 billion in funding from Aprogen I&C, Inc.Neofect Co., Ltd. announced a private placement to issue 2,290,950 common shares at an issue price of KRW 873 per share for the gross proceeds of KRW 1,999,999,350 on October 15, 2024. The transaction will include participation from new investor Aprogen I&C, Inc. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on October 23, 2024.
お知らせ • Oct 09Neofect Co., Ltd. announced that it expects to receive KRW 999.999675 million in funding from Cj Consulting Co., Ltd., YR Invest Co., LtdNeofect Co., Ltd. announced a private placemen to issue 1,145,475 shares at an issue price of KRW 873 per share for the gross proceeds of KRW 999,999,675 on October 8, 2024. The transaction will include participation from new investors Cj Consulting Co., Ltd. 916,380 shares and YR Invest Co., Ltd 229,095 shares. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on October 21, 2024.
分析記事 • Jun 19There Is A Reason Neofect Co.,Ltd's (KOSDAQ:290660) Price Is UndemandingWith a price-to-sales (or "P/S") ratio of 1.6x Neofect Co.,Ltd ( KOSDAQ:290660 ) may be sending bullish signals at the...
お知らせ • Apr 10Neofect Co.,Ltd announced that it has received KRW 4.99999991 billion in funding from Scandi New Technology Association No. 278On April 9, 2024, Neofect Co.,Ltd. closed the transaction. The company issued 2,722,323 common shares at an issue price of KRW 1,102 for the gross proceeds of KRW 2,999,999,946 in its second and final tranche closing. The company has received KRW 4,999,999,910 in the transaction.
お知らせ • Dec 28Neofect Co.,Ltd announced that it has received KRW 4.99999991 billion in funding from Kyowon Life, Inc., Scandi New Technology Association No. 278On December 26, 2023, Neofect Co.,Ltd. closed the transaction. The company received KRW 1,999,999,964 in its second and final tranche closing.
New Risk • Nov 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.0b market cap, or US$28.7m).
New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩6.0b free cash flow). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (₩35.6b market cap, or US$27.3m).
お知らせ • Jan 17Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 999.999245 million.Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 999.999245 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 692,041 Price\Range: KRW 1445 Transaction Features: Subsequent Direct Listing
分析記事 • Mar 17NeofectLtd's (KOSDAQ:290660) Stock Price Has Reduced 19% In The Past YearIt's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
Is New 90 Day High Low • Feb 24New 90-day low: ₩3,015The company is down 16% from its price of ₩3,570 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Feb 03New 90-day low: ₩3,105The company is down 19% from its price of ₩3,810 on 05 November 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Jan 18New 90-day low: ₩3,215The company is down 16% from its price of ₩3,815 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Dec 28New 90-day low: ₩3,405The company is down 25% from its price of ₩4,545 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Dec 08New 90-day low: ₩3,510The company is down 10.0% from its price of ₩3,905 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 2.0% over the same period.
Reported Earnings • Dec 06Third quarter 2020 earnings released: ₩309 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: ₩4.35b (down 15% from 3Q 2019). Net loss: ₩3.80b (loss widened 7.6% from 3Q 2019).
お知らせ • Nov 12Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 18.59 billion.Neofect Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 18.59 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,500,000 Price\Range: KRW 2860 Discount Per Security: KRW 64.35 Transaction Features: ESOP Related Offering; Rights Offering
Is New 90 Day High Low • Oct 26New 90-day low: ₩3,540The company is down 29% from its price of ₩5,020 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period.
